Shire’s cytomegalovirus therapy wins ‘Breakthrough’ status

An experimental drug being developed by Shire to treat cytomegalovirus (CMV) infection has been given a boost in the US with a ‘Breakthrough Therapy Designation’.

• Source: pharmatimes
• 512
• January 8, 2018